MEETINGS - Seminar and workshop entitled "The IVD (in-vitro diagnostic) Directive - Entering the Transition Period" (UK) March 2000:
This article was originally published in Clinica
The British In Vitro Diagnostics Association (BIVDA) will hold a seminar and workshop entitled The IVD Directive - Entering the Transition Period in Leicester, UK, on March 30-31. The seminar will cover the UK statutory instrument, progress: with transposition in other EU member states; grey areas in the directive; and use of human tissue samples for product development. Two series of workshops, one for attendees new to the field and the other for those with experience, will cover specific aspects of the directive. For more information contact Caroline Czermark at BIVDA. Tel: +44 020 7957 4633. Fax: +44 020 7957 4644. Email: email@example.com
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.